ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 704

Decreased Number of Endothelial Progenitor Cells in Systemic Sclerosis Patients with Early Disease

Fernando V. Andrigueti, Maria I. Arismendi, Pâmela C.C. Ebbing and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: endothelial cells, growth factors and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud’s – Clinical Aspects and Therapeutics

Session Type: Abstract Submissions (ACR)

Background/Purpose: Microangiopathy and endothelial dysfunction are present in early phases of Systemic sclerosis (SSc), resulting in decreased blood flow and tissue ischemia. Several mechanisms including insufficient angiogenesis, and defective vasculogenesis mediated by endothelial progenitor cells (EPCs), might be involved in the vascular abnormalities in SSc patients. However, different data have been reported regarding the number and function of EPCs in different clinical subsets of SSc patients. This study aimed to evaluate the circulating number and the in vitro culture of EPCs in SSc patients with early disease compared to healthy controls.

Methods: Thirty-one consecutive SSc female patients (mean age 42.7 years) with less than four years of Raynaud’s phenomenon (RP) and 20 age-matched healthy women (mean age 39.9 years) were included. All patients fulfilled the ACR classification criteria for SSc (1980) or the LeRoy and Medsger criteria (2001). Peripheral blood samples (30mL) were collected from each subject at rest. Flow cytometry was performed to quantify the absolute number of EPCs. EPCs were identified by the co-expression of CD34, CD133 and vascular endothelial growth factor receptor type 2 (VEGFR2) and were expressed as the number of EPCs per 106 lymphomononuclear (LMN) cells. Besides, in vitro culture of EPCs was performed, and the number of EPC colony-forming units (CFU) per well was quantified in each sample. All procedures were performed according the EULAR recommendations and executed immediately after blood collection. Plasma VEGF levels were assessed by ELISA. p<0.05 were considered statistically significant.

Results: Among SSc patients, the mean duration of RP was 3.75±1.96 years and the mean duration of the first SSc symptom other than RP was 3.24±1.85 years. Digital ulcers were present in ten patients. SSc patients showed decreased number of EPCs (108.6±87.2 vs 246.8±241.4 /106LMN, respectively, p=0.04), and decreased number of EPC CFUs compared to controls (14.6±9.1 vs 20.9±11.5 CFUs, respectively, p=0.034). There was no significant difference in the number of EPCs between SSc patients with digital ulcers and those without digital ulcers at the time of the evaluation (90.5±73.2 vs 121.4±96.5 /106LMN, respectively, p=0.4). There was a positive correlation between the number of circulating EPCs and the number of EPC CFUs. There was no difference in VEGF levels between patients and controls (88.3±57.9 vs 83.8±74.6 ng/mL, p=0.34).

Conclusion: The present study showed originally decreased EPCs in SSc patients with early disease onset, suggesting presence of defective vasculogenesis in early stages of the disease. Therefore, EPCs could be an important therapeutic target for preventing vascular complications in patients with early stages of SSc.


Disclosure:

F. V. Andrigueti,
None;

M. I. Arismendi,
None;

P. C. C. Ebbing,
None;

C. Kayser,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-number-of-endothelial-progenitor-cells-in-systemic-sclerosis-patients-with-early-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology